News

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention

Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities …

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention Read More »

Cluster Headaches

Cluster Headaches, often called ‘suicide headaches‘, around 130,000 people in the UK suffer from the debilitating condition, cluster headaches. They are excruciating attacks of pain on one side of the head. The pain can be so bad that sufferers sometimes harm themselves to distract themselves from the pain. Now, a new study has been launched …

Cluster Headaches Read More »

Positive Phase III data for migraine drug Fremanezumab

Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of …

Positive Phase III data for migraine drug Fremanezumab Read More »

Under the hat

The European Headache Federation (EHF) and the European Migraine Headache Alliance (EMHA) are pleased to announce the 21st March as the first Cluster Headache Day as part of the ‘What’s the Under the Hat?’ public awareness campaign. Cluster headache is one of the worst pains known to man and affects up to 4 in 1,000 …

Under the hat Read More »

Scroll to Top